Evidence map›Paper›PMID 30550561›Full record

ArticlePLoS biology2018

CD71+VISTA+ erythroid cells promote the development and function of regulatory T cells through TGF-β.

Shima Shahbaz, Najmeh Bozorgmehr, Petya Koleva, Afshin Namdar, Juan Jovel, Roy A Fava, Shokrollah Elahi

Open access · goldAbstract read
In one paragraph

Article in PLoS biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. CD45BMC gastroenterology · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Shima ShahbazDepartment of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Najmeh BozorgmehrDepartment of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Petya KolevaDepartment of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Afshin NamdarDepartment of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Juan JovelThe Applied Genomics Core, Office of Research, University of Alberta, Edmonton, Canada.
Roy A FavaDepartment of Veterans Affairs Medical Center, Research Service, White River Junction, Vermont, United States of America.
Shokrollah ElahiDepartment of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.ORCID 0000-0002-7215-2009
University of Alberta · CADartmouth–Hitchcock Medical Center · US

Funding

CIHR 353953CIHR 360929CIHR 385988
6 · The paper itself

Abstract

Cell-surface transferrin receptor (CD71+) erythroid cells are abundant in newborns with immunomodulatory properties. Here, we show that neonatal CD71+ erythroid cells express significant levels of V-domain Immunoglobulin (Ig) Suppressor of T Cell Activation (VISTA) and, via constitutive production of transforming growth factor (TGF)- β, play a pivotal role in promotion of naïve CD4+ T cells into regulatory T cells (Tregs). Interestingly, we discovered that CD71+VISTA+ erythroid cells produce significantly higher levels of TGF-β compared to CD71+VISTA- erythroid cells and CD71+ erythroid cells from the VISTA knock-out (KO) mice. As a result, CD71+VISTA+ erythroid cells-compared to CD71+VISTA- and CD71+ erythroid cells from the VISTA KO mice-significantly exceed promotion of naïve CD4+ T cells into induced Tregs (iTreg) via TGF-β in vitro. However, depletion of CD71+ erythroid cells had no significant effects on the frequency of Tregs in vivo. Surprisingly, we observed that the remaining and/or newly generated CD71+ erythroid cells following anti-CD71 antibody administration exhibit a different gene expression profile, evidenced by the up-regulation of VISTA, TGF-β1, TGF-β2, and program death ligand-1 (PDL-1), which may account as a compensatory mechanism for the maintenance of Treg population. We also observed that iTreg development by CD71+ erythroid cells is mediated through the inhibition of key signaling molecules phosphorylated protein kinase B (phospho-Akt) and phosphorylated mechanistic target of rapamycin (phospho-mTOR). Finally, we found that elimination of Tregs using forkhead box P3 (FOXP3)-diptheria toxin receptor (DTR) mice resulted in a significant expansion in the frequency of CD71+ erythroid cells in vivo. Collectively, these studies provide a novel, to our knowledge, insight into the cross-talk between CD71+ erythroid cells and Tregs in newborns. Our results highlight the biological role of CD71+ erythroid cells in the neonatal period and possibly beyond.

Indexed as

AnimalsAntigens, CDCD4-Positive T-LymphocytesErythroid CellsFemaleForkhead Transcription FactorsLymphocyte ActivationMaleMembrane ProteinsMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutPhosphorylationReceptors, Cell SurfaceReceptors, TransferrinAntigens, CDCD71 antigenForkhead Transcription FactorsMembrane ProteinsReceptors, Cell SurfaceReceptors, TransferrinTransforming Growth Factor betaVsir protein, mouse

Identifiers

PMID30550561
PMCPMC6310287
OpenAlexW2903877638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.